Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 394

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 394
---
 the Company’s convertible preferred stock was converted into a warrant to acquire a number of shares of Class A common stock obtained by dividing the warrant as-if-exercised liquidation preference by $10.00, with the exercise price equal to the total Company warrant exercise amount divided by the number of shares of Class A common stock issuable upon exercise. |

| 8. | The Company’s convertible notes automatically converted into shares of New CERo Series A Preferred Stock, at a conversion price equal to $1,000 per share. |

PIPE Financing

In February 2024, New CERo consummated a private
placement of shares of New CERo Series A Preferred Stock, par value $ per share (the “New CERo Series A Preferred Stock”),
warrants to purchase shares of common stock (the “Common Warrants”) and warrants to purchase shares of Series
A Preferred Stock (the “Preferred Warrants” and, together with the Common Warrants, the “PIPE Warrants”), pursuant
to the Amended and Restated Securities Purchase Agreement, dated February 14, 2024, by and among the Company, PBAX and certain accredited
investors (the “Initial Investors”) for aggregate cash proceeds to New CERo of approximately $ million. On April 1, 2024,
we consummated a private placement of shares of Series B Preferred Stock, pursuant to the Securities Purchase Agreement, dated March
28, 2024, by and among us and certain accredited investors (the “Additional Investors” and, together with the Initial Investors,
the “PIPE Investors”), for aggregate cash proceeds to us of approximately $ million. Such private placement is expected
to close on or around April 1, 2024. A portion of such Series A Preferred Stock was issued as consideration for the cancellation of outstanding
indebtedness or securities of the Company, including a promissory note of PBAX and the Company’s convertible notes. Such transactions
collectively are referred to as the “PIPE Financing.”

F-68 Up to 4,000,000 Shares of Common Stock Up to 4,000,000 Pre-Funded Warrants to Purchase up to 4,000,000 Shares of Common Stock Up to 4,000,000 Common Warrants to Purchase up to 4,000,000 Shares of Common Stock Up to 4,000,000 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrants and Common Warrants CERO